Context: Most cervical tumors are classified as squamous cell carcinoma or adenocarcinoma, both of which are associated with persistent human papillomavirus (HPV) infection. Although other (rare) types represent less than 5% of all cervical carcinomas, it is necessary that these more unusual tumors be studied in the current era of papillomavirus vaccine development, especially in regions with high incidence of cervical cancer.
Objective: To compare papillomavirus types found in histologically rare cervical carcinomas (n = 29) with those types found in common cervical carcinomas (n = 14) archived at the Institute of Cancer in Mexico City, Mexico.
Design: Paraffin-embedded tissues were received and sectioned at the Louisiana State University Health Sciences Center at Shreveport. One section for each block was stained and examined by 2 pathologists. Specific histologies were categorized into 2 broad groups: common (squamous cell carcinoma or adenocarcinoma) or rare (adenosquamous, papillary, villoglandular, anaplastic, transitional, spindle, adenoid basal, colloid, neuroendocrine, and glassy cell carcinomas). Papillomavirus typing results were based on Roche Molecular Systems line-blot assay.
Results: No significant difference was found for dual HPV types (21% of both groups), positivity for HPV-16 (66% of rare tumors and 71% of common tumors), or absence of HPV types 16 or 18, although the rare cancers had a greater tendency toward more unusual HPV types (8/29 rare tumors and 1/14 common tumors had no HPV- 16 or HPV-18 DNA). Non-HPV-16/18 types found only in rare tumors included HPV types 52, 84, 26, 35, and 58.
Conclusions: Rare types of cervical carcinoma also are associated with papillomavirus, most with types similar to those found in common cervical neoplasias.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5858/2004-128-553-HPTORC | DOI Listing |
Purpose: Radiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk cancer.
Methods: Patients had squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity, oropharynx, or larynx, with one or more risk factors warranting postoperative RT.
Cancer Med
January 2025
Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Background: Cervical cancer poses a significant threat to women's health and encompasses various histological types, including squamous cell carcinoma (SCC), cervical adenocarcinoma (CA), and adenosquamous carcinoma. CA, in particular, presents a formidable challenge in clinical management due to its low early detection rate, pronounced aggressiveness, high recurrence rate, and mortality, compounded by the complexities associated with late-stage treatment. There is limited understanding of the similarities and differences in the pathogenesis mechanisms between CA and SCC, such as tumor heterogeneity and the tumor immune microenvironment (TME).
View Article and Find Full Text PDFCancer Rep (Hoboken)
January 2025
Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Background: PD-L1 expression in tumors and immune cells is a biomarker for the efficacy of anti-PD-1 antibody (APA) therapy across diverse cancers. Based on the results from the KEYNOTE-048 trial, pembrolizumab monotherapy is indicated for platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) with a positive combined positive score (CPS). Conversely, nivolumab is utilized for platinum-pretreated R/M-HNSCC regardless of the positive tumor proportion score (TPS) following the results of the CheckMate-141; however, its subgroup analysis indicated that TPS-positive population tended to have a relatively high overall response rate and progression-free survival (PFS).
View Article and Find Full Text PDFHead Neck
January 2025
Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Objectives: We aimed to compare the outcomes of patients with T1-T2N0M0 glottic squamous cell carcinoma who underwent either partial laryngectomy (PL) or radiotherapy (RT).
Methods: A retrospective analysis of 562 patients treated with RT (n = 151) or PL (n = 411) was conducted. The Kaplan-Meier method was used to estimate outcomes.
Front Oncol
January 2025
Department of Thyroid Surgery, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Precision Medicine Laboratory of Molecular Biology and Translational Medicine on Differentiated Thyroid Carcinoma, The China-Japan Union Hospital of Jilin University, Changchun, China.
Objective: To review a rare case of a lateral neck mass pathologically confirmed as an encapsulated papillary thyroid carcinoma in our center for complementing the lack of management of rare cases, and to explore the differentiation of primary ectopic thyroid carcinoma and metastatic disease in the context of the presence of malignant tumors within the situ thyroid gland.
Methods: We searched for studies on lateral neck ectopic thyroid cancer to compare and analyze it with metastatic carcinoma of the thyroid gland in terms of clinical features, imaging manifestations, pathological features at molecular level, and treatment principles.
Results: Based on available data, we concluded that the mass of this patient was consistent with metastatic lateral neck ectopic thyroid carcinoma.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!